Icatibant Accord

Icatibant, the active ingredient in Icatibant Accord, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL subcutaneous solution for injection use. By competitively blocking the bradykinin B2 receptor, it reduces vasodilation and vascular permeability, providing rapid relief of hereditary angioedema attacks caused by C1‑inhibitor deficiency in affected patients.

GNH USA supplies Icatibant Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

Hereditary angioedema (type I): rapid relief of acute swelling attacks. Hereditary angioedema (type II): rapid relief of acute swelling attacks. Hereditary angioedema (any type) acute attacks: reduces duration and severity of episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate headache. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure. - Angioedema at injection site: extensive swelling. - Infection: localized infection of the injection site. - Thrombocytopenia: rare decrease in platelet count. - Cardiovascular events: rare chest pain or arrhythmia.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events.

Assess patient history: confirm diagnosis of hereditary angioedema before use. Monitor for hypersensitivity: observe for signs of allergic reaction after injection. Avoid in patients with known hypersensitivity: do not administer to individuals allergic to icatibant or excipients. Use with caution in patients on ACE inhibitors: increased bradykinin levels may affect response. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin pathways or cardiovascular status.

Major Interactions (Avoid): - Concurrent ACE inhibitor therapy: may increase bradykinin levels and reduce efficacy. - Co‑administration with other bradykinin B2 antagonists: additive pharmacologic effect unknown. - Simultaneous use of injectable biologics: may increase risk of injection‑site reactions.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of hypersensitivity. - Diuretics: potential for additive blood‑pressure effects. - Estrogen‑containing contraceptives: may alter frequency of angioedema attacks.